Pixium Vision completes 10 implants in its Iris II study

Pixium Vision, a company developing and commercializing innovative bionic vision systems, has completed 10 implants in its Iris II study.

Iris II is a bionic vision system equipped with a bio-inspired camera and a 150 electrodes epi-retinal implant with a proprietary design intended to be explantable and eventually upgradable for patients who have lost sight due to Retinitis Pigmentosa (RP).

All implanted patients will now follow their re-education program as defined in the ongoing European multi-centric study for Iris II which was launched in January 2016, said the company in its press release.

Khalid Ishaque, CEO of Pixium, said: “The completion of enrollment demonstrates important interest in our innovative IrisII bionic vision system. Many in the ophthalmology and artificial vision community look forward to the interim updates which can be expected later in 2017 which will be important for Pixium Vision’s development of retinal implant systems. The company is dedicated to conceive, develop and bring meaningful bionic vision innovations to surgeons, which shall enable them to treat patients who have lost sight to retinal dystrophies.”